Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.41 |
| ▸ | METAP1 | P53582 | 7/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 2/20 | 0.34 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26897366 | 0.83 | CTSC (0.34) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL1157636 | 0.79 | ARG1 (0.60) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL8084363 | 0.79 | ARG1 (0.60) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL1157633 | 0.79 | ARG1 (0.60) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL13659832 | 0.79 | NOS2 (0.44) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL8024940 | 0.79 | NOS2 (0.44) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL17324230 | 0.79 | METAP2 (0.37) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL28472089 | 0.78 | ARG1 (0.58) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL8024937 | 0.78 | ARG1 (0.40) | METAP2METAP1ARG1ARG2NOS2 | |
| SCHEMBL20792012 | 0.76 | GABRP (0.36) | BHMTBHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | SGMS1, ENPP2, SGMS2 | METAP2 156/4885METAP1 152/4885ARG1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.